1275 related articles for article (PubMed ID: 27413711)
1. Non-small cell lung cancer: current treatment and future advances.
Zappa C; Mousa SA
Transl Lung Cancer Res; 2016 Jun; 5(3):288-300. PubMed ID: 27413711
[TBL] [Abstract][Full Text] [Related]
2. Multimodality therapy in the treatment of lung cancer.
Rivera MP
Semin Respir Crit Care Med; 2004; 25 Suppl 1():3-10. PubMed ID: 16088515
[TBL] [Abstract][Full Text] [Related]
3. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
6. Screening for patients with non-small cell lung cancer who could survive long term chemotherapy.
Wu XY; Huang XE
Asian Pac J Cancer Prev; 2015; 16(2):647-52. PubMed ID: 25684501
[TBL] [Abstract][Full Text] [Related]
7. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
Arbour KC; Riely GJ
JAMA; 2019 Aug; 322(8):764-774. PubMed ID: 31454018
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
9. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
Osmani L; Askin F; Gabrielson E; Li QK
Semin Cancer Biol; 2018 Oct; 52(Pt 1):103-109. PubMed ID: 29183778
[TBL] [Abstract][Full Text] [Related]
10. Association of p53/p21 expression and cigarette smoking with tumor progression and poor prognosis in non-small cell lung cancer patients.
Xie D; Lan L; Huang K; Chen L; Xu C; Wang R; Shi Y; Wu X; Wang L; Liu Y; Lu B
Oncol Rep; 2014 Dec; 32(6):2517-26. PubMed ID: 25333671
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Silvestri GA; Rivera MP
Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
[TBL] [Abstract][Full Text] [Related]
12. The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer.
Sacco PC; Maione P; Guida C; Gridelli C
Curr Clin Pharmacol; 2017; 12(1):4-10. PubMed ID: 27908252
[TBL] [Abstract][Full Text] [Related]
13. The evolving locally-advanced non-small cell lung cancer landscape: Building on past evidence and experience.
Méry B; Guy JB; Swalduz A; Vallard A; Guibert C; Almokhles H; Ben Mrad M; Rivoirard R; Falk AT; Fournel P; Magné N
Crit Rev Oncol Hematol; 2015 Nov; 96(2):319-27. PubMed ID: 26095618
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant immunotherapy for non-small cell lung cancer.
Tucker ZC; Laguna BA; Moon E; Singhal S
Cancer Treat Rev; 2012 Oct; 38(6):650-61. PubMed ID: 22226940
[TBL] [Abstract][Full Text] [Related]
15. Non-small cell lung cancer. Part I: Biology, diagnosis, and staging.
Ihde DC; Minna JD
Curr Probl Cancer; 1991; 15(2):61-104. PubMed ID: 1649734
[TBL] [Abstract][Full Text] [Related]
16. [Impact of TNM staging and treatment mode on the prognosis of non-small cell lung cancer].
Yu DP; Bai LQ; Xu SF; Han M; Wang ZT
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):465-8. PubMed ID: 19950561
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced (stages III and IV) non-small-cell lung cancer.
Sweeney CJ; Sandler AB
Curr Probl Cancer; 1998; 22(2):85-132. PubMed ID: 9580849
[TBL] [Abstract][Full Text] [Related]
18. Non-Small-cell Lung Cancer Patients With Adenocarcinoma Morphology Have a Better Outcome Compared With Patients Diagnosed With Non-Small-cell Lung Cancer Favor Adenocarcinoma.
Shiran I; Heller E; Jessel S; Kamer I; Daniel-Meshulam I; Navon R; Urban D; Onn A; Bar J
Clin Lung Cancer; 2017 May; 18(3):316-323.e1. PubMed ID: 28237243
[TBL] [Abstract][Full Text] [Related]
19. Differentially expressed and activated proteins associated with non small cell lung cancer tissues.
Nigro E; Imperlini E; Scudiero O; Monaco ML; Polito R; Mazzarella G; Orrù S; Bianco A; Daniele A
Respir Res; 2015 Jun; 16(1):74. PubMed ID: 26104294
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
